.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a median follow-up of 11 months, people with metastatic gastrointestinal growths that acquired biomarker-matched therapies based on spreading tumor DNA profiling revealed a greater professional benefit than those getting unparalleled therapy.